The genotypic inhibitory quotient: A predictive factor of atazanavir response in HIV-1-infected treatment-experienced patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 48, Issue 2, 2008, Pages 177-180

  Solas, Caroline ^a   Colson, Philippe ^a   Ravaux, Isabelle ^b   Poizot Martin, Isabelle ^c   Moreau, Jacques ^d   Lacarelle, Bruno ^a   Tamalet, Catherine ^a  

^a TIMONE HOSPITAL   (France)

^b HÔPITAL DE LA CONCEPTION   (France)

^c HÔPITAL SAINTE MARGUERITE   (France)

^d HÔPITAL NORD   (France)

Author keywords

Atazanavir; Drug resistance mutations; Genotypic inhibitory quotient; HIV 1; Virologic response

Indexed keywords

ATAZANAVIR; PROTEINASE INHIBITOR; RITONAVIR; OLIGOPEPTIDE; PYRIDINE DERIVATIVE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MALE; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; VIRUS LOAD; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIVIRAL RESISTANCE; BLOOD; CD4 LYMPHOCYTE COUNT; DRUG EFFECT; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MUTATION; VIROLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MUTATION; OLIGOPEPTIDES; PYRIDINES;

EID: 46449138764     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318164226a     Document Type: Article

References (15)

1. Rapport YP. 2006: Prise en charge médicale des personnes infectées par le VIH. Recommandations du groupe d'experts. Rapport 2006 sous la direction du Pr P Yeni. Paris: Medecine-Sciences, Flammarion, 2006.
2. Burger D, Hugen P, Reiss P, et al. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS. 2003;17:1157-1165.
3. Durant J, Clevenbergh P, Garraffo R, et al. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacologic data from the Viradapt Study. AIDS. 2000;14:1333-1339.
4. Lorenzi P, Yerly S, Abderrakim K, et al. Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with HIV infection treated with ritonavir plus saquinavir. AIDS. 1997;11:F95-F99.
5. Bossi P, Peytavin G, Ait-Mohand H, et al. GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy. HIV Med. 2004;5:352-359.
6. Clevenbergh P, Garraffo R, Durant J, et al. PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic drug monitoring of protease inhibitors: 12 week results. AIDS. 2002;16:2311-2315.
7. Marcelin A, Lamotte C, Delaugerre C, et al. Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2003;47:594-600.
8. Marcelin A, Cohen-Codar I, King MS, et al. Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2005;49:1720-1726.
9. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med. 2004;350:1023-1035.
10. Barrios A, Rendon AL, Gallego O. Predictors of virological response to atazanavir in protease inhibitor-experienced patients. HIV Clin Trials. 2004;5:201-205.
11. Henry M, Tourres C, Colson P, et al. Coexistence of the K65R/L74V and/ or K65R/T215Y mutations on the same HIV-1 genome. J Clin Virol. 2006;37:227-230.
12. Solas C, Gagnieu MC, Lanet F, et al. Population pharmacokinetic of atazanavir in HIV-infected patient [abstract 52]. Presented at: Sixth International Workshop on Clinical Pharmacology of HIV Therapy; 2005; Quebec.
13. Pellegrin I, Breilh D, Ragnaud JM, et al. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study). Antivir Ther. 2006;11: 421-429.
14. Cleijsen R, Van de Ende M, Kroon F, et al. Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice [abstract 36]. Presented at: Eighth International Workshop on Clinical Pharmacology of HIV Therapy; 2007; Budapest.
15. trough is associated with efficacy and safety at 24 weeks: definition of therapeutic range [abstract 60]. Presented at: Sixth International Workshop on Clinical Pharmacology of HIV Therapy; 2006; Quebec.